Form 4: Arcturus Controller Granted 10,000 Stock Options

Arcturus Therapeutics Holdings Inc. Controller Joseph Roberts received a grant of 10,000 employee stock options with an exercise price of $6.52.

Summary

• Joseph Roberts, Controller of Arcturus Therapeutics Holdings Inc. (ARCT), was granted 10,000 employee stock options.
• The options have an exercise price of $6.52 per share.
• The grant date for these options was December 17, 2025.
• The options expire on December 17, 2035.
• Vesting begins with 25% on December 17, 2026, and the remainder vests in equal monthly increments over the subsequent 36 months.
• The options were granted under the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to an officer, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests, but does not convey significant new financial performance information.

Positives

• The grant of stock options serves as an incentive for Joseph Roberts, aligning his interests with long-term shareholder value creation.
• It reflects ongoing compensation and retention strategies for key management personnel.

Negatives

• Potential for future dilution if the options are exercised, though this is a standard aspect of equity compensation plans.

Future Outlook

The vesting schedule for the granted options extends over four years, indicating a long-term incentive structure for the Controller, Joseph Roberts, tied to the company's future performance.

Industry Context

The grant of employee stock options is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like Arcturus Therapeutics, to attract, retain, and incentivize key talent. Such equity compensation aligns management's financial interests with the long-term growth and success of the company, a standard approach in high-growth, R&D-intensive sectors.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from incentivized management.
• Employees (specifically Joseph Roberts): Receives a significant equity incentive, enhancing compensation and long-term wealth potential.

Next Steps

• Continued vesting of the granted stock options according to the specified schedule.
• Potential future exercise of options by Joseph Roberts, subject to vesting and market conditions.

Key Dates

Keywords

Arcturus Therapeutics, ARCT, Joseph Roberts, Controller, Stock Options, Employee Incentive Plan, Insider Transaction, SEC Form 4, Equity Compensation